Bagsværd, Denmark, 21 March 2019 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following resolutions were adopted:

Financial year 2018 and 2019

  • The Company's statutory Annual Report 2018.
  • The actual remuneration of the Board of Directors for 2018 and the remuneration level for 2019.
  • The final dividend for 2018 of DKK 5.15 for each Novo Nordisk A or B share of DKK 0.20. The total dividend for 2018 of DKK 8.15 includes both the interim dividend of DKK 3.00 for each Novo Nordisk A and B share of DKK 0.20 which was paid in August 2018 and a final dividend of DKK 5.15 for each Novo Nordisk A and B share of DKK 0.20 to be paid in March 2019.

Elections

  • Re-election of Helge Lund as chairman of the Board of Directors.
  • Re-election of Jeppe Christiansen as vice chairman of the Board of Directors.
  • Re-election of Brian Daniels, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay as members of the Board of Directors.
  • Election of Laurence Debroux as new member of the Board of Directors.
  • Re-appointment of PricewaterhouseCoopers Statsautoriseret Revisionspartner-selskab as the Company's auditor.

Shares and capital

  • Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 382,512,800 to DKK 372,512,800. The Company's A share capital of DKK 107,487,200 remains unchanged, whereby the Company's share capital will amount to DKK 480,000,000.
  • Authorisation to the Board of Directors until the Annual General Meeting 2020 to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.
  • Authorisation to the Board of Directors to increase the Company's share capital for a period of two years until 21 March 2021 by a total of nominally DKK 2,000,000 for the authorisation under Article 5.3 in the Articles of Association (for employees without pre-emptive rights for shareholders) and a total of nominally DKK 48,000,000 for the authorisation under Article 5.4, (with or without pre-emptive rights for existing shareholders) subject to a total cap of nominally DKK 48,000,000 for both authorisations under Articles 5.3 and 5.4.

Other

  • Revised Remuneration Principles were adopted.
  • A proposal from a shareholder to reduce prices if the return on equity exceeded 7%, was not adopted.

Composition of the Board of Directors and its committees

After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees, is now composed as follows:

  • Helge Lund (chairman of the Board and chairman of the Nomination Committee)
  • Jeppe Christiansen (vice chairman of the Board and chairman of the Remuneration Committee)
  • Brian Daniels (member of the Remuneration Committee and the Research & Development Committee)
  • Laurence Debroux (member of the Audit Committee)
  • Andreas Fibig (member of the Audit Committee)
  • Sylvie Grégoire (member of the Nomination Committee, the Audit Committee and the Research & Development Committee)
  • Liz Hewitt (chairman of the Audit Committee and member of the Remuneration Committee)
  • Mette Bøjer Jensen (employee representative and member of the Nomination Committee)
  • Kasim Kutay (member of the Nomination Committee)
  • Anne Marie Kverneland (employee representative and member of the Remuneration Committee)
  • Martin Mackay (chairman of the Research & Development Committee)
  • Thomas Rantzau (employee representative and member of the Research & Development Committee)
  • Stig Strøbæk (employee representative and member of the Audit Committee) 

Further information

Media:    
Mette Kruse Danielsen +45 4442 3883 mkd@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

 

Company Announcement No 19/2019

 

Attachment